





2024-2025

FISCAL YEAR REPORT

Dear Friends, Supporters, and
Families,

As we close out our second fiscal year, we reflect with deep gratitude on the progress we've made together. We set ambitious goals: to complete our drug repurposing program and identify new compounds to help our patients improve function in cognition and motor movement, complete our biomarker study, and host our first in-person MCOPS12 symposium. Thanks to your unwavering support, we are proud to report that most of these goals have been realized.

REFLECTING ON A CURE FOR SOPHIA AND FRIENDS SECOND YEAR



GLOBAL CONNECTIONS: OUR FIRST IN-PERSON CONFERENCE



This year marked a major milestone—our first in-person RARB family conference!

We were honored to welcome families from USA, Canada, Austria, Australia, New Zealand, and Ireland, with 20% of our global RARB community in attendance.

- We reimbursed hotel and transfer costs for all families traveling outside of Canada.
- We hosted a family and researcher dinner following the conference.
- Throughout the weekend, priceless networking occurred between families and researchers—building bridges of understanding and collaboration.

*“Our experience at the conference was life changing to watch our daughter truly come out of her shell and feel comfortable to be herself was a blessing! We have a worldwide family who truly understands.” – **Collins Family***

*“To finally meet and be able to hug these amazing people responsible for spearheading research towards a treatment for our little ones was truly life changing” – **Flint Family***

**GOAL 1:
COMPLETE
DRUG
REPURPOSING
STUDY**

**GOAL 2:
CONTINUE
DEVELOPING
ASO THERAPY**

**GOAL 3:
COMPLETE OUR
BIOMARKER STUDY
TO SUPPORT
CLINICAL TRIALS**

**RESEARCH
HIGHLIGHTS**



OUR TEAM'S MILESTONES

GOAL 1: COMPLETE DRUG REPURPOSING STUDY

As a first step, our drug repurposing study identified a defect (mitochondrial dysfunction) in a MCOPS12 patient-derived cell model

This important finding will serve as a readout for the subsequent screening of 10,000 compounds at NCATS as of the end of our 24/25 fiscal year


We are hopeful to have results in the first quarter of our 25/26 fiscal year to begin either off-label use or clinical trials depending on which compounds are identified.




DRUG DEVELOPMENT: DRUG REPURPOSING PROGRAMS II

- **Program 2 (at Everlum Bio, USA; start Q2 2024, completed in Q4 2025):**


- **~10000 drugs** (2400 FDA approved, 2600 completed Ph. I/II clinical trials, 5000 „natural compounds“ e.g. vitamins, minerals) are **tested in a patient-derived (R387C) neuronal stem cell (NSC) model**
- **Readouts: functional**



Mitochondrial dysfunction in neuronal cells
(both in patients (R387C) and mouse models)



Detectable by a Mitochondrial Membrane Potential (MMP) Assay*



(healthy) control NSC patient NSC

- **Drug screening in Q4 2025:** for **successful candidates** there are **two options**:
 - off-label use (for market approved drugs & „natural compounds“)
 - MCOPS12 clinical trial (for drugs in clinical trials)

**MMP assay principle: in healthy cells, a dye accumulates in mitochondria showing red fluorescence.*

When mitochondrial membrane potential collapses after a chemical (FCCP) treatment, the dye remains in cytoplasm with green fluorescence.

GOAL 2: CONTINUE DEVELOPING A PERSONALIZED ASO THERAPY

to lay the groundwork for a possible ASO therapy for additional MCOPS12 patients

What is an ASO Therapy and Why Does It Matter?

Antisense Oligonucleotide (ASO) therapy is a cutting-edge approach that targets the RNA—the messenger that carries instructions from DNA to produce proteins. ASOs are short, synthetic strands of nucleic acids designed to bind to specific RNA sequences.



This can:

- Reduce harmful protein production
- Correct splicing errors
- Block translation of toxic proteins



Current ASO Achievements:

- Long read sequencing & bioinformatics identified several targets for ASO candidates
- A patient iPSCs-derived neuronal cell model was generated to test ASOs for efficacy
- Five ASO candidates showed significant knockdown of the mutant allele without affecting the wild type (healthy version).




For MCOPS12 patients

ASO therapy offers a precision tool to silence the mutant RARB gene while preserving the healthy version.

This targeted (allele-specific) approach minimizes side effects and holds promise for personalized genetic treatment.


DRUG DEVELOPMENT: PERSONALIZED ASO THERAPY

Antisense Oligonucleotide (ASO) for allele-selective mRNA knockdown



GOAL 3: COMPLETE OUR BIOMARKER STUDY TO SUPPORT CLINICAL TRIALS

A biomarker study in a MCOPS12 mouse model is ongoing and we are hoping to begin biomarker discovery in MCOPS12 patients during our 2025-2026 fiscal year.



Why Biomarkers Matter

Biomarkers are measurable characteristics of the body that indicate abnormal processes or disease. They are essential in clinical trials, often serving as primary or secondary endpoints to evaluate the effectiveness of a treatment.

For MCOPS12, we are now working to identify neurological disease-specific biomarkers in patients—such as proteins and metabolites in blood or cerebrospinal fluid (CSF), and brain imaging markers. These biomarkers will be critical in helping us move forward with clinical trials once promising drug compounds are identified.



ACKNOWLEDGING OUR FOUNDATIONAL SUPPORT



rare
village
FOUNDATION




CAPITAL
GROUP™



CHU Sainte-Justine


Michaud Research Lab-
CHU Sainte-Justine
Research Center
Université de Montréal

Prof. Jacques Michaud
Montréal, Canada



Thank you to our research partners at CHU Sainte-Justine who made our first in-person MCOPS12 family conference a success and continue their diligent work on our natural history study! We remain deeply grateful to Rare Village Foundation, whose fiscal sponsorship enables us to continue fundraising and secure critical grants. We also extend heartfelt thanks to Capital Group, whose continued advocacy and generosity have amplified our mission and expanded our reach.

FINANCIAL TRANSPARENCY & DONOR IMPACT



THANKS TO YOUR GENEROSITY, A CURE FOR SOPHIA AND FRIENDS RAISED JUST OVER

\$84,000

These donations and many more directly funded our research projects, family conference, and operational costs—reflected in the pie chart below:


In addition to our corporate partner

Capital Group

We'd like to thank the following donors who have each contributed over \$1500 for the last two years

- A Cure for Sienna
- Christine D'Amico
- Dawn Middleton
- Rischel Pike
- Amy Stein
- Barbara Vittuozo
- Scott Yacyshyn

2024-2025 EXPENSE BREAKDOWN





A Cure for Sophia and Friends Advisory Board
Chelsey Oliver *Secretary*

Rischel Pike *Treasurer*

Reinhard Pell *Research and Drug Development*

S Gary Sutherland *Information
Specialist/Website Designer*

and special thanks to **Heather Cawood**
incoming Social Media Director

As we reflect on another year of progress, we remain humbled by the generosity and belief you've placed in our mission. Your support fuels our research, strengthens our community, and brings hope to families around the world.

With heartfelt gratitude,

Rachel Sutherland

Executive Director, A Cure for Sophia and Friends
www.acureforsophiaandfriends.com



HERE'S TO 2025- 2026!

THANK YOU FOR BEING PART OF OUR JOURNEY. LET'S
MAKE THIS YEAR EVEN MORE AMAZING TOGETHER!

